Comment
Author: Admin | 2025-04-28
PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis. Roflumilast is 25-300X more potent than the two other FDA-approved PDE4 inhibitors used in dermatology and has a well-established safety profile with more than 1 million patient years of exposure in clinicaluse.Ensifentrine: Verona Pharma Ensifentrine is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. This dual inhibition enables it to combine bronchodilator and anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD, including corticosteroids, beta2-agonists and anti-muscarinics. It is currently in Phase III stage of development for Chronic obstructive pulmonary disease and is being developed VeronaPharma.PDE Inhibitors: Therapeutic AssessmentThis segment of the report provides insights about the different PDE Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:Major Players in PDE InhibitorsThere are approx. 40+ key companies which are developing the therapies for PDE Inhibitors. The companies which have their PDE Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Arcutis Biotherapeutics.PhasesThis report covers around 40+ products under different phases of clinical development likeLate stage products (Phase III)Mid-stage products (Phase II)Early-stage product (Phase I) along with the details ofPre-clinical and Discovery stage candidatesDiscontinued & Inactive candidatesRoute of AdministrationPDE Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such asOralParenteralIntravenousSubcutaneousTopical.Molecule TypeProducts have been categorized under various Molecule types such asMonoclonal AntibodyPeptidesPolymerSmall moleculeGene therapyProduct TypeDrugs have been categorized under various product types like Mono, Combination and Mono/Combination.PDE Inhibitors: Pipeline Development ActivitiesThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PDE Inhibitors therapeutic drugs key players involved in developing key drugs.Pipeline Development ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PDE Inhibitors drugs.PDE Inhibitors Report InsightsPDE Inhibitors Pipeline AnalysisTherapeutic AssessmentUnmet NeedsImpact of DrugsPDE Inhibitors Report AssessmentPipeline Product ProfilesTherapeutic AssessmentPipeline AssessmentInactive drugs assessmentUnmet NeedsKey QuestionsCurrent Treatment Scenario and Emerging Therapies:How many companies are developing PDE Inhibitors drugs?How many PDE Inhibitors drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PDE Inhibitors?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PDE Inhibitors therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for PDE Inhibitors and their status?What are the key designations that have been granted to the emerging drugs?Key PlayersArcutis BiotherapeuticsChiesi FarmaceuticiImara IncVerona PharmaEisai IncvTv TherapeuticsTetra TherapeuticsPalobiofarmaKey
Add Comment